Sareum Holdings (GB:SAR) has released an update.
Sareum Holdings PLC, a biotech firm specializing in kinase inhibitors for cancer and autoimmune diseases, has issued new ordinary shares following a warrant exercise by RiverFort Global Opportunities. This warrant exercise has generated £110,698.60 for the company, with no further warrants held by RiverFort. The newly issued shares are expected to be admitted for trading on the AIM segment of the London Stock Exchange.
For further insights into GB:SAR stock, check out TipRanks’ Stock Analysis page.
